Filtered By:
Drug: Simvastatin

This page shows you your search results in order of relevance. This is page number 6.

Order by Relevance | Date

Total 124 results found since Jan 2013.

Rapid analysis of hypolipidemic drugs in a live zebrafish assay
In this study, taking advantage of the transparency of larval zebrafish, we developed a zebrafish hyperlipidemia model for drug screening and efficacy assessment. Zebrafish at 5 d.p.f (days post fertilization) were fed with 0.1% egg yolk for 48h (hours), followed by drug treatment for 24h or 48h. Tested drugs were administered into the zebrafish by direct soaking. Drug effect was evaluated based on quantitative analysis of Oil Red O (ORO) in zebrafish vena caudalis. Results All 5 human hypolipidemic drugs (simvastatin, lovastatin, ezetimibe, bezafibrate, hyodesoxycholic acid) showed significant hypolipidemic effects (p &a...
Source: Journal of Pharmacological and Toxicological Methods - December 13, 2014 Category: Drugs & Pharmacology Source Type: research

Sex differences in cardiovascular outcome during progression of aortic valve stenosis
Conclusions In the SEAS study, women and men had similar rates of AS progression and AS-related events. However, women had lower total mortality and ischaemic CV event rate than men independent of confounders. Trial registration number ClinicalTrials.gov identifier: NCT00092677.
Source: Heart - January 14, 2015 Category: Cardiology Authors: Cramariuc, D., Rogge, B. P., Lonnebakken, M. T., Boman, K., Bahlmann, E., Gohlke-Barwolf, C., Chambers, J. B., Pedersen, T. R., Gerdts, E. Tags: Open access, Drugs: cardiovascular system, Echocardiography, Hypertension, Interventional cardiology, Aortic valve disease, Clinical diagnostic tests, Epidemiology Valvular heart disease Source Type: research

High-Dose Simvastatin for Aneurysmal Subarachnoid Hemorrhage: Multicenter Randomized Controlled Double-Blinded Clinical Trial Clinical Sciences
Conclusions— High-dose simvastatin treatment should not be prescribed routinely for aneurysmal subarachnoid hemorrhage. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT01077206.
Source: Stroke - January 26, 2015 Category: Neurology Authors: Wong, G. K. C., Chan, D. Y. C., Siu, D. Y. W., Zee, B. C. Y., Poon, W. S., Chan, M. T. V., Gin, T., Leung, M., HDS-SAH Investigators, Zhu, Liang, Tan, Lee, Wong, Chan, Po, Woo, Chan Tags: Cerebral Aneurysm, AVM, & Subarachnoid hemorrhage, Neuroprotectors Clinical Sciences Source Type: research

Differential Effects of Strong and Regular Statins on the Clinical Outcome of Patients With Chronic Kidney Disease Following Coronary Stent Implantation.
Conclusions:In patients with mild-to-moderate CKD, only strong statins were associated with lower risk compared with no statin, but regular statins were not. It is possible that taking a strong statin from the early stage of CKD is useful for suppression of cardiovascular events. PMID: 25739954 [PubMed - as supplied by publisher]
Source: Circulation Journal - February 24, 2015 Category: Cardiology Authors: Ishii M, Hokimoto S, Akasaka T, Fujimoto K, Miyao Y, Kaikita K, Oshima S, Nakao K, Shimomura H, Tsunoda R, Hirose T, Kajiwara I, Matsumura T, Nakamura N, Yamamoto N, Koide S, Oka H, Morikami Y, Sakaino N, Matsui K, Ogawa H, on behalf of the Kumamoto Inter Tags: Circ J Source Type: research

Cholesterol – the super-stealthy invisible illness
Sourced from The Hysterectomy Association: Hysterectomy Association - Hysterectomy Association - hysterectomy, menopause and hormone replacement therapy (hrt) information and support for women. As far as invisible illnesses go, they don’t come much stealthier than high cholesterol. It’s easily ignored because it builds up gradually, often showing no symptoms whatsoever. A person with high or increasing cholesterol levels will most likely feel perfectly healthy. It’s a scary though that the first sign of high cholesterol may be a heart attack or stroke – and could even prove fatal! Fortunately, medical professionals...
Source: The Hysterectomy Association - March 26, 2015 Category: OBGYN Authors: Linda Parkinson-Hardman Tags: Health Conditions cholesterol invisible illness Source Type: news

Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT.
CONCLUSIONS: Significantly more patients treated with ezetimibe/simvastatin met prespecified and exploratory dual LDL-C and hs-CRP targets than patients treated with simvastatin alone. Reaching both LDL-C and hs-CRP targets was associated with improved outcomes after multivariable adjustment. Clinical Trial Registration-URL: http://www.clinicaltrials.gov; Unique identifier: NCT00202878. PMID: 26330412 [PubMed - as supplied by publisher]
Source: Circulation - September 1, 2015 Category: Cardiology Authors: Bohula EA, Giugliano RP, Cannon CP, Zhou J, Murphy SA, White JA, Tershakovec AM, Blazing MA, Braunwald E Tags: Circulation Source Type: research

Minocycline-induced pigmentation of the skin and nails
Introduction Minocycline is an effective treatment for inflammatory cutaneous conditions, such as acne vulgaris and rosacea, infectious conditions and has recently been investigated for its neuroprotective properties. However, treatment with minocycline can induce iatrogenic pigmentation, affecting both the skin and other organs. Recognition of these changes may avoid unnecessary investigations. This image case report aims to remind clinicians of this often-persistent side effect of minocycline. Case A 73-year-old man attended the dermatology outpatient clinic with a 20-year history of progressive swelling of the nose, ass...
Source: Postgraduate Medical Journal - October 23, 2015 Category: Journals (General) Authors: Ali, F. R., Yiu, Z. Z., Ogden, S. Tags: Liver disease, Urology, Genetics, Immunology (including allergy), Drugs: infectious diseases, Movement disorders (other than Parkinsons), Stroke, Hypertension, Psychotic disorders (incl schizophrenia), Pneumonia (respiratory medicine), Connective tissue d Source Type: research

Association Between Paradoxical HDL Cholesterol Decrease and Risk of Major Adverse Cardiovascular Events in Patients Initiated on Statin Treatment in a Primary Care Setting
Conclusions Paradoxical statin-induced reduction in HDL-C was relatively common and was associated with increased risk of MACE.
Source: Clinical Drug Investigation - December 30, 2015 Category: Drugs & Pharmacology Source Type: research

Risks of Adverse Events Following Coprescription of Statins and Calcium Channel Blockers: A Nationwide Population-Based Study
In this study, 5857 patients received coprescription of CYP3A4-metabolized statins and CCBs that inhibit CYP3A4. There were no differences in comorbidity or use of antihypertensive drugs between patients who received CYP3A4-metabolized statins and those who received non-CYP3A4-metabolized statins. Patients who received CYP3A4-metabolized statins had significantly higher risk of acute kidney injury (adjusted odds ratio [OR] = 2.12; 95% CI = 1.35–3.35), hyperkalemia (adjusted OR = 2.94; 95% CI = 1.36–6.35), acute myocardial infarction (adjusted OR = 1.55; 95% CI = 1.16–2.07), and acute ischemic ...
Source: Medicine - January 1, 2016 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research

Merck Receives Complete Response Letter from the U.S. FDA for ZETIA® (ezetimibe) and VYTORIN® (ezetimibe and simvastatin)
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter regarding Merck's Supplemental New Drug Applications for ZETIA® and VYTORIN® for the reduction of the risk of cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina, or need for revascularization) in patients with coronary heart disease. Language: ...
Source: Merck.com - Product News - February 15, 2016 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news

Reply Adding Ezetimibe to Simvastatin for the Secondary Prevention of Cardiovascular Disease: Is it Useful?
In response to Drs. Mascitelli and Goldstein, we previously reported in the primary publication of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) that there was no difference between ezetimibe plus simvastatin as compared with simvastatin alone with respect to cardiovascular death or all-cause mortality (1). Because the focus of the present paper is total cardiovascular events (2), we did not re-report all-cause mortality because the data were previously published, and a subject can only die once. This lack of difference was expected in IMPROVE-IT because prior trials of intensive-dose ve...
Source: Journal of the American College of Cardiology - June 21, 2016 Category: Cardiology Source Type: research

Merck Receives Complete Response Letter from the U.S. FDA for ZETIA ® (ezetimibe) and VYTORIN® (ezetimibe and simvastatin)
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter regarding Merck ' s Supplemental New Drug Applications for ZETIA ® and VYTORIN® for the reduction of the risk of cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina, or need for revascularization) in patients with coronary heart disease. Language: English ...
Source: Merck.com - Product News - February 15, 2016 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news

Assessing Optimal Blood Pressure in Patients with Asymptomatic Aortic Valve Stenosis: The SEAS Study.
CONCLUSIONS: -Optimal BP seems to be systolic 130-139 mmHg and diastolic 70-90 mmHg in these patients with asymptomatic AS and no manifest atherosclerotic disease or diabetes. Clinical Trial Registration-http://www.clinicaltrials.gov; NCT00092677. PMID: 27486164 [PubMed - as supplied by publisher]
Source: Circulation - August 1, 2016 Category: Cardiology Authors: Nielsen OW, Sajadieh A, Sabbah M, Greve AM, Olsen MH, Boman K, Nienaber CA, Kesäniemi YA, Pedersen TR, Willenheimer R, Wachtell K Tags: Circulation Source Type: research

On-Treatment Analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT)
Conclusions This analysis provides additional support for the efficacy and safety of adding Ez to S in this high-risk, post-ACS population.
Source: American Heart Journal - September 22, 2016 Category: Cardiology Source Type: research

Anti-atherosclerosis and cardio-protective effects of the Angong Niuhuang Pill on a high fat and vitamin D3 induced rodent model of atherosclerosis
Conclusions We have demonstrated that ANP has robust ant-atherosclerosis and cardio-protective effects on a high-fat and vitamin D3 – induced rodent model of atherosclerosis due to its antiplatelet aggregation, lipid regulatory, antioxidant, anti-inflammatory and anti-apoptotic properties. Graphical abstract
Source: Journal of Ethnopharmacology - December 24, 2016 Category: Drugs & Pharmacology Source Type: research